Fig. 1: COLIBRI study design. | Nature Communications

Fig. 1: COLIBRI study design.

From: Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

Fig. 1: COLIBRI study design.The alternative text for this image may have been generated using AI.

Iconographies (cells, antibodies, blood tubes, uterus) adapted from Servier Medical Art (https://smart.servier.com), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Servier Medical C cycle, D day, ECOG Eastern Cooperative Oncology Group, EOT end of treatment, FIGO International Federation of Gynecology and Obstetrics, LACC locally advanced cervical cancer, q4w every 4 weeks, RTCT chemoradiation (comprising cisplatin 40 mg/m2 or carboplatin AUC2 every week for 5 weeks, external beam radiotherapy 45 Gy in 25 fractions at 1.8 Gy/fraction, 5 fractions per week, and brachytherapy [high-dose rate: 27.5–30 Gy; low/pulsed-dose rate: 35–40 Gy]). aOptional cervical tumor sample during surgery. bMandatory blood sample and optional biopsy at progression.

Back to article page